Novo Nordisk deepened its push for oral alternatives to injectable cardiometabolic drugs through a strategic partnership with Orbis Medicines. The multi-target deal could total up to $1.4 billion in payments and royalties, leveraging Orbis’s nGen platform to design macrocycles intended to improve oral bioavailability and membrane permeability.